Belvedere Trading
TERN

Belvedere Trading’s Terns Pharmaceuticals TERN Stock Holding History

Belvedere Trading’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-25,963
Closed -$169K – 963
2023
Q4 		$169K Sell
25,963
-1,908
-7% -$10.1K ﹤0.01% 376
2023
Q3 		$140K Sell
27,871
-7,457
-21% -$47.3K ﹤0.01% 271
2023
Q2 		$309K Buy
+35,328
New +$412K ﹤0.01% 220

Other funds holding TERN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Belvedere Trading's TERN Position: Q1 2024 in Review

Belvedere Trading sold out of Terns Pharmaceuticals (TERN) in Q1 2024, closing a stake of 25,963 shares — an estimated $169K sold.

Belvedere Trading first reported a position in TERN in Q2 2023 and held it in 3 quarters. The position peaked at $309K in Q2 2023. 112 funds tracked by Wall St. Rank hold TERN as of Q1 2024.

  • Belvedere Trading reported no remaining Terns Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Belvedere Trading sold 25,963 Terns Pharmaceuticals shares in Q1 2024, an estimated $169K.
  • Belvedere Trading first reported a position in Terns Pharmaceuticals in Q2 2023 and held it in 3 quarters.
  • Belvedere Trading's Terns Pharmaceuticals position peaked at $309K in Q2 2023.
  • 112 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2024.

Based on Belvedere Trading's 13F filing for Q1 2024, filed 9 May 2024.